Secondary resistance to imatinib in child with chronic myeloid leukemia as result of mutations in BCR-ABL1 kinase domain.

Autor: Pawelec, Katarzyna Martyna, Albrecht, Katarzyna
Zdroj: Acta Haematologica Polonica; 2023, Vol. 54 Issue 4, p263-265, 3p
Abstrakt: The article presents a case study of an 11-year-old girl diagnosed with chronic myeloid leukemia (CML) who initially responded well to imatinib treatment but developed secondary resistance due to a BCR-ABL1 kinase domain mutation.Topics covered in the article include the management of chronic myeloid leukemia in pediatric patients, the emergence of resistance to tyrosine kinase inhibitors, and the significance of mutational analysis in guiding treatment decisions for CML.
Databáze: Complementary Index